Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT)

Seminars in Cancer Biology

Volumn 22, Issue 5-6, 2012, Pages 417-427

  Warzecha, Claude C ^a   Carstens, Russ P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alternative splicing; EMT; Epithelial cells; ESRP; Mesenchymal cells; Metastasis

Indexed keywords

ARHGAP17 PROTEIN; CATENIN; DYNAMIN II; EPB41L5 PROTEIN; EPITHELIAL SPLICING REGULATORY PROTEIN 1; EPITHELIAL SPLICING REGULATORY PROTEIN 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; INSULIN RECEPTOR SUBSTRATE; INSULIN RECEPTOR SUBSTRATE P53; LEUCINE RICH REPEAT IN FLII INTERACTING PROTEIN 2; MAGI1 PROTEIN; MENA PROTEIN; MESSENGER RNA; NUMB PROTEIN; PROTEIN KINASE; PROTEIN P120; REGULATOR PROTEIN; SCAFFOLD PROTEIN; SCRIB PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR 7 LIKE 2; TRANSCRIPTION FACTOR TWIST; TRANSFORMING GROWTH FACTOR BETA ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; BREAST CANCER; CANCER GROWTH; CELL ADHESION; CELL POLARITY; CELL SHAPE; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST GROWTH FACTOR RECEPTOR 2 GENE; FOCAL ADHESION; GENE EXPRESSION; HIGH THROUGHPUT SEQUENCING; METASTASIS; NONHUMAN; PLURIPOTENT STEM CELL; PROTEIN PROCESSING; REVIEW; RNA SPLICING; SPLICEOSOME; TRANSCRIPTION REGULATION;

ALTERNATIVE SPLICING; ANIMALS; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; RNA ISOFORMS; RNA PRECURSORS; RNA, MESSENGER;

EID: 84866320228     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2012.04.003     Document Type: Review

References (107)

1. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
2. Dressler G.R. The cellular basis of kidney development. Annual Review of Cell and Developmental Biology 2006, 22:509-529.
3. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Developmental Cell 2008, 14:818-829.
4. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nature Reviews Molecular Cell Biology 2006, 7:131-142.
5. Peinado H., Olmeda D., Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nature Reviews Cancer 2007, 7:415-428.
6. Wang E.T., Sandberg R., Luo S., Khrebtukova I., Zhang L., Mayr C., et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008, 456:470-476.
7. Pan Q., Shai O., Lee L.J., Frey B.J., Blencowe B.J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nature Genetics 2008, 40:1413-1415.
8. Stamm S., Ben-Ari S., Rafalska I., Tang Y., Zhang Z., Toiber D., et al. Function of alternative splicing. Gene 2005, 344:1-20.
9. Nilsen T.W., Graveley B.R. Expansion of the eukaryotic proteome by alternative splicing. Nature 2010, 463:457-463.
10. Chen M., Manley J.L. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nature Reviews Molecular Cell Biology 2009, 10:741-754.
11. Jurica M.S., Moore M.J. Pre-mRNA splicing: awash in a sea of proteins. Molecular Cell 2003, 12:5-14.
12. Martinez-Contreras R., Cloutier P., Shkreta L., Fisette J.F., Revil T., Chabot B. hnRNP proteins and splicing control. Advances in Experimental Medicine and Biology 2007, 623:123-147.
13. Long J.C., Caceres J.F. The SR protein family of splicing factors: master regulators of gene expression. Biochemical Journal 2009, 417:15-27.
14. Hertel K.J. Combinatorial control of exon recognition. Journal of Biological Chemistry 2008, 283:1211-1215.
15. Ule J., Ule A., Spencer J., Williams A., Hu J.S., Cline M., et al. Nova regulates brain-specific splicing to shape the synapse. Nature Genetics 2005, 37:844-852.
16. Kalsotra A., Xiao X., Ward A.J., Castle J.C., Johnson J.M., Burge C.B., et al. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:20333-20338.
17. Keene J.D. RNA regulons: coordination of post-transcriptional events. Nature Reviews Genetics 2007, 8:533-543.
18. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nature Reviews Cancer 2010, 10:116-129.
19. Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., Ornitz D.M. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. Journal of Biological Chemistry 2006, 281:15694-15700.
20. Carstens R.P., Eaton J.V., Krigman H.R., Walther P.J., Garcia-Blanco M.A. Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene 1997, 15:3059-3065.
21. Savagner P., Valles A.M., Jouanneau J., Yamada K.M., Thiery J.P. Alternative splicing in fibroblast growth factor receptor 2 is associated with induced epithelial-mesenchymal transition in rat bladder carcinoma cells. Molecular Biology of the Cell 1994, 5:851-862.
22. De Medina S.G., Popov Z., Chopin D.K., Southgate J., Tucker G.C., Delouvee A., et al. Relationship between E-cadherin and fibroblast growth factor receptor 2b expression in bladder carcinomas. Oncogene 1999, 18:5722-5726.
23. Revest J.M., Spencer-Dene B., Kerr K., De Moerlooze L., Rosewell I., Dickson C. Fibroblast growth factor receptor 2-IIIb acts upstream of Shh and Fgf4 and is required for limb bud maintenance but not for the induction of Fgf8, Fgf10, Msx1, or Bmp4. Developmental Biology 2001, 231:47-62.
24. De Moerlooze L., Spencer-Dene B., Revest J.M., Hajihosseini M., Rosewell I., Dickson C. An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Development 2000, 127:483-492.
25. Arman E., Haffner-Krausz R., Gorivodsky M., Lonai P. Fgfr2 is required for limb outgrowth and lung-branching morphogenesis. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:11895-11899.
26. Davis M.A., Ireton R.C., Reynolds A.B. A core function for p120-catenin in cadherin turnover. Journal of Cell Biology 2003, 163:525-534.
27. Grosheva I., Shtutman M., Elbaum M. Bershadsky AD. p120 catenin affects cell motility via modulation of activity of Rho-family GTPases: a link between cell-cell contact formation and regulation of cell locomotion. Journal of Cell Science 2001, 114:695-707.
28. Yanagisawa M., Huveldt D., Kreinest P., Lohse C.M., Cheville J.C., Parker A.S., et al. A p120 catenin isoform switch affects Rho activity, induces tumor cell invasion, and predicts metastatic disease. Journal of Biological Chemistry 2008, 283:18344-18354.
29. Keirsebilck A., Bonne S., Staes K., van Hengel J., Nollet F., Reynolds A., et al. Molecular cloning of the human p120ctn catenin gene (CTNND1): expression of multiple alternatively spliced isoforms. Genomics 1998, 50:129-146.
30. Ohkubo T., Ozawa M. The transcription factor Snail downregulates the tight junction components independently of E-cadherin downregulation. Journal of Cell Science 2004, 117:1675-1685.
31. Sarrio D., Perez-Mies B., Hardisson D., Moreno-Bueno G., Suarez A., Cano A., et al. Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene 2004, 23:3272-3283.
32. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule. Nature Reviews Cancer 2011, 11:254-267.
33. Bennett K.L., Modrell B., Greenfield B., Bartolazzi A., Stamenkovic I., Peach R., et al. Regulation of CD44 binding to hyaluronan by glycosylation of variably spliced exons. Journal of Cell Biology 1995, 131:1623-1633.
34. Terpe H.J., Stark H., Prehm P., Gunthert U. CD44 variant isoforms are preferentially expressed in basal epithelial of non-malignant human fetal and adult tissues. Histochemistry 1994, 101:79-89.
35. Hong R.L., Pu Y.S., Chu J.S., Lee W.J., Chen Y.C., Wu C.W. Correlation of expression of CD44 isoforms and E-cadherin with differentiation in human urothelial cell lines and transitional cell carcinoma. Cancer Letters 1995, 89:81-87.
36. Iida N., Bourguignon L.Y. Coexpression of CD44 variant (v10/ex14) and CD44S in human mammary epithelial cells promotes tumorigenesis. Journal of Cellular Physiology 1997, 171:152-160.
37. Warzecha C.C., Sato T.K., Nabet B., Hogenesch J.B., Carstens R.P. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Molecular Cell 2009, 33:591-601.
38. Brown R.L., Reinke L.M., Damerow M.S., Perez D., Chodosh L.A., Yang J., et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. Journal of Clinical Investigation 2011, 121:1064-1074.
39. Sherman L., Wainwright D., Ponta H., Herrlich P. A splice variant of CD44 expressed in the apical ectodermal ridge presents fibroblast growth factors to limb mesenchyme and is required for limb outgrowth. Genes and Development 1998, 12:1058-1071.
40. Krause M., Dent E.W., Bear J.E., Loureiro J.J., Gertler F.B. Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration. Annual Review of Cell and Developmental Biology 2003, 19:541-564.
41. Gates J., Mahaffey J.P., Rogers S.L., Emerson M., Rogers E.M., Sottile S.L., et al. Enabled plays key roles in embryonic epithelial morphogenesis in Drosophila. Development 2007, 134:2027-2039.
42. Bear J.E., Svitkina T.M., Krause M., Schafer D.A., Loureiro J.J., Strasser G.A., et al. Antagonism between Ena/VASP proteins and actin filament capping regulates fibroblast motility. Cell 2002, 109:509-521.
43. Goswami S., Philippar U., Sun D., Patsialou A., Avraham J., Wang W., et al. Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo. Clinical and Experimental Metastasis 2009, 26:153-159.
44. Roussos E.T., Balsamo M., Alford S.K., Wyckoff J.B., Gligorijevic B., Wang Y., et al. Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer. Journal of Cell Science 2011, 124:2120-2131.
45. Pino M.S., Balsamo M., Di Modugno F., Mottolese M., Alessio M., Melucci E., et al. Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines. Clinical Cancer Research 2008, 14:4943-4950.
46. Hovhannisyan R.H., Carstens R.P. Heterogeneous ribonucleoprotein m is a splicing regulatory protein that can enhance or silence splicing of alternatively spliced exons. Journal of Biological Chemistry 2007, 282:36265-36274.
47. Baraniak A.P., Chen J.R., Garcia-Blanco M.A. Fox-2 mediates epithelial cell-specific fibroblast growth factor receptor 2 exon choice. Molecular and Cellular Biology 2006, 26:1209-1222.
48. Hovhannisyan R.H., Carstens R.P. A novel intronic cis element, ISE/ISS-3, regulates rat fibroblast growth factor receptor 2 splicing through activation of an upstream exon and repression of a downstream exon containing a noncanonical branch point sequence. Molecular and Cellular Biology 2005, 25:250-263.
49. Warzecha C.C., Shen S., Xing Y., Carstens R.P. The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events. RNA Biology 2009, 6:546-562.
50. Dominguez C., Fisette J.F., Chabot B., Allain F.H. Structural basis of G-tract recognition and encaging by hnRNP F quasi-RRMs. Nature Structural and Molecular Biology 2010, 17:853-861.
51. Barberan-Soler S., Zahler A.M. Alternative splicing regulation during C. elegans development: splicing factors as regulated targets. PLoS Genetic 2008, 4:e1000001.
52. Yochem J., Bell L.R., Herman R.K. The identities of sym-2, sym-3 and sym-4, three genes that are synthetically lethal with mec-8 in Caenorhabditis elegans. Genetics 2004, 168:1293-1306.
53. Wakabayashi-Ito N., Belvin M.P., Bluestein D.A., Anderson K.V. Fusilli, an essential gene with a maternal role in Drosophila embryonic dorsal-ventral patterning. Developmental Biology 2001, 229:44-54.
54. Huang Y., Fernandez S.V., Goodwin S., Russo P.A., Russo I.H., Sutter T.R., et al. Epithelial to mesenchymal transition in human breast epithelial cells transformed by 17beta-estradiol. Cancer Research 2007, 67:11147-11157.
55. Onder T.T., Gupta P.B., Mani S.A., Yang J., Lander E.S., Weinberg R.A. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Research 2008, 68:3645-3654.
56. Thomson S., Petti F., Sujka-Kwok I., Mercado P., Bean J., Monaghan M., et al. A systems view of epithelial-mesenchymal transition signaling states. Clinical and Experimental Metastasis 2011, 28:137-155.
57. Horiguchi K., Sakamoto K., Koinuma D., Semba K., Inoue A., Inoue S., et al. TGF-beta drives epithelial-mesenchymal transition through deltaEF1-mediated downregulation of ESRP. Oncogene 2011.
58. Shapiro I.M., Cheng A.W., Flytzanis N.C., Balsamo M., Condeelis J.S., Oktay M.H., et al. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genetic 2011, 7:e1002218.
59. Taube J.H., Herschkowitz J.I., Komurov K., Zhou A.Y., Gupta S., Yang J., et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:15449-15454.
60. Ghigna C., Giordano S., Shen H., Benvenuto F., Castiglioni F., Comoglio P.M., et al. Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Molecular Cell 2005, 20:881-890.
61. Collesi C., Santoro M.M., Gaudino G., Comoglio P.M. A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Molecular and Cellular Biology 1996, 16:5518-5526.
62. Zhou Y.Q., He C., Chen Y.Q., Wang D., Wang M.H. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene 2003, 22:186-197.
63. Goncalves V., Matos P., Jordan P. Antagonistic SR proteins regulate alternative splicing of tumor-related Rac1b downstream of the PI3-kinase and Wnt pathways. Human Molecular Genetics 2009, 18:3696-3707.
64. Radisky D.C., Levy D.D., Littlepage L.E., Liu H., Nelson C.M., Fata J.E., et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005, 436:123-127.
65. Valacca C., Bonomi S., Buratti E., Pedrotti S., Baralle F.E., Sette C., et al. Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene. Journal of Cell Biology 2010, 191:87-99.
66. Lapuk A., Marr H., Jakkula L., Pedro H., Bhattacharya S., Purdom E., et al. Exon-level microarray analyses identify alternative splicing programs in breast cancer. Molecular Cancer Research 2010, 8:961-974.
67. Vajda N.A., Brimacombe K.R., LeMasters K.E., Ladd A.N. Muscleblind-like 1 is a negative regulator of TGF-beta-dependent epithelial-mesenchymal transition of atrioventricular canal endocardial cells. Developmental Dynamics 2009, 238:3266-3272.
68. Moore M.J., Silver P.A. Global analysis of mRNA splicing. RNA 2008, 14:197-203.
69. Ozsolak F., Milos P.M. RNA sequencing: advances, challenges and opportunities. Nature Reviews Genetics 2011, 12:87-98.
70. Warzecha C.C., Jiang P., Amirikian K., Dittmar K.A., Lu H., Shen S., et al. An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition. EMBO Journal 2010, 29:3286-3300.
71. Prat A., Parker J.S., Karginova O., Fan C., Livasy C., Herschkowitz J.I., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Research 2010, 12:R68.
72. Hennessy B.T., Gonzalez-Angulo A.M., Stemke-Hale K., Gilcrease M.Z., Krishnamurthy S., Lee J.S., et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Research 2009, 69:4116-4124.
73. Sarrio D., Rodriguez-Pinilla S.M., Hardisson D., Cano A., Moreno-Bueno G., Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Research 2008, 68:989-997.
74. Blick T., Widodo E., Hugo H., Waltham M., Lenburg M.E., Neve R.M., et al. Epithelial mesenchymal transition traits in human breast cancer cell lines. Clinical and Experimental Metastasis 2008, 25:629-642.
75. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527.
76. Krugmann S., Jordens I., Gevaert K., Driessens M., Vandekerckhove J., Hall A. Cdc42 induces filopodia by promoting the formation of an IRSp53:Mena complex. Current Biology 2001, 11:1645-1655.
77. Lim K.B., Bu W., Goh W.I., Koh E., Ong S.H., Pawson T., et al. The Cdc42 effector IRSp53 generates filopodia by coupling membrane protrusion with actin dynamics. Journal of Biological Chemistry 2008, 283:20454-20472.
78. Okamura-Oho Y., Miyashita T., Yamada M. Distinctive tissue distribution and phosphorylation of IRSp53 isoforms. Biochemical and Biophysical Research Communications 2001, 289:957-960.
79. Sato K., Watanabe T., Wang S., Kakeno M., Matsuzawa K., Matsui T., et al. Numb controls E-cadherin endocytosis through p120 catenin with aPKC. Molecular Biology of the Cell 2011, 22:3103-3119.
80. Wang Z., Li S.S. Numb A new player in EMT. Cell Adhesion and Migration 2010, 4:176-179.
81. Wang Z., Sandiford S., Wu C., Li S.S. Numb regulates cell-cell adhesion and polarity in response to tyrosine kinase signalling. EMBO Journal 2009, 28:2360-2373.
82. Dho S.E., French M.B., Woods S.A., McGlade C.J. Characterization of four mammalian numb protein isoforms. Identification of cytoplasmic and membrane-associated variants of the phosphotyrosine binding domain. Journal of Biological Chemistry 1999, 274:33097-33104.
83. Medici D., Hay E.D., Goodenough D.A. Cooperation between Snail and LEF-1 transcription factors is essential for TGF-beta1-induced epithelial-mesenchymal transition. Molecular Biology of the Cell 2006, 17:1871-1879.
84. Weise A., Bruser K., Elfert S., Wallmen B., Wittel Y., Wohrle S., et al. Alternative splicing of Tcf7l2 transcripts generates protein variants with differential promoter-binding and transcriptional activation properties at Wnt/beta-catenin targets. Nucleic Acids Research 2010, 38:1964-1981.
85. Cao H., Garcia F., McNiven M.A. Differential distribution of dynamin isoforms in mammalian cells. Molecular Biology of the Cell 1998, 9:2595-2609.
86. Liu Y.W., Surka M.C., Schroeter T., Lukiyanchuk V., Schmid S.L. Isoform and splice-variant specific functions of dynamin-2 revealed by analysis of conditional knock-out cells. Molecular Biology of the Cell 2008, 19:5347-5359.
87. Zhang Y.E. Non-Smad pathways in TGF-beta signaling. Cell Research 2009, 19:128-139.
88. Wells C.D., Fawcett J.P., Traweger A., Yamanaka Y., Goudreault M., Elder K., et al. A Rich1/Amot complex regulates the Cdc42 GTPase and apical-polarity proteins in epithelial cells. Cell 2006, 125:535-548.
89. Laura R.P., Ross S., Koeppen H., Lasky L.A. MAGI-1: a widely expressed, alternatively spliced tight junction protein. Experimental Cell Research 2002, 275:155-170.
90. Liu J., Bang A.G., Kintner C., Orth A.P., Chanda S.K., Ding S., et al. Identification of the Wnt signaling activator leucine-rich repeat in Flightless interaction protein 2 by a genome-wide functional analysis. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:1927-1932.
91. Qin Y., Capaldo C., Gumbiner B.M., Macara I.G. The mammalian Scribble polarity protein regulates epithelial cell adhesion and migration through E-cadherin. Journal of Cell Biology 2005, 171:1061-1071.
92. Vaira V., Faversani A., Dohi T., Maggioni M., Nosotti M., Tosi D., et al. Aberrant overexpression of the cell polarity module scribble in human cancer. American Journal of Pathology 2011, 178:2478-2483.
93. Dow L.E., Kauffman J.S., Caddy J., Zarbalis K., Peterson A.S., Jane S.M., et al. The tumour-suppressor Scribble dictates cell polarity during directed epithelial migration: regulation of Rho GTPase recruitment to the leading edge. Oncogene 2007, 26:2272-2282.
94. Hirano M., Hashimoto S., Yonemura S., Sabe H., Aizawa S. EPB41L5 functions to post-transcriptionally regulate cadherin and integrin during epithelial-mesenchymal transition. Journal of Cell Biology 2008, 182:1217-1230.
95. Lee J.D., Silva-Gagliardi N.F., Tepass U., McGlade C.J., Anderson K.V. The FERM protein Epb4.1l5 is required for organization of the neural plate and for the epithelial-mesenchymal transition at the primitive streak of the mouse embryo. Development 2007, 134:2007-2016.
96. Gosens I., Sessa A., den Hollander A.I., Letteboer S.J., Belloni V., Arends M.L., et al. FERM protein EPB41L5 is a novel member of the mammalian CRB-MPP5 polarity complex. Experimental Cell Research 2007, 313:3959-3970.
97. Laprise P., Beronja S., Silva-Gagliardi N.F., Pellikka M., Jensen A.M., McGlade C.J., et al. The FERM protein Yurt is a negative regulatory component of the Crumbs complex that controls epithelial polarity and apical membrane size. Developmental Cell 2006, 11:363-374.
98. Christensen A.K., Jensen A.M. Tissue-specific requirements for specific domains in the FERM protein Moe/Epb4.1l5 during early zebrafish development. BMC Developmental Biology 2008, 8:3.
99. Li R., Liang J., Ni S., Zhou T., Qing X., Li H., et al. A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell 2010, 7:51-63.
100. Di Modugno F., DeMonte L., Balsamo M., Bronzi G., Nicotra M.R., Alessio M., et al. Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines. Cancer Research 2007, 67:2657-2665.
101. van der Flier A., Kuikman I., Kramer D., Geerts D., Kreft M., Takafuta T., et al. Different splice variants of filamin-B affect myogenesis, subcellular distribution, and determine binding to integrin [beta] subunits. Journal of Cell Biology 2002, 156:361-376.
102. Besse A., Lamothe B., Campos A.D., Webster W.K., Maddineni U., Lin S.C., et al. TAK1-dependent signaling requires functional interaction with TAB2/TAB3. Journal of Biological Chemistry 2007, 282:3918-3928.
103. Ceriani M., Scandiuzzi C., Amigoni L., Tisi R., Berruti G., Martegani E. Functional analysis of RalGPS2, a murine guanine nucleotide exchange factor for RalA GTPase. Experimental Cell Research 2007, 313:2293-2307.
104. Hogervorst F., Admiraal L.G., Niessen C., Kuikman I., Janssen H., Daams H., et al. Biochemical characterization and tissue distribution of the A and B variants of the integrin alpha 6 subunit. Journal of Cell Biology 1993, 121:179-191.
105. Roovers K., Wagner S., Storbeck C.J., O'Reilly P., Lo V., Northey J.J., et al. The Ste20-like kinase SLK is required for ErbB2-driven breast cancer cell motility. Oncogene 2009, 28:2839-2848.
106. Barac A., Basile J., Vazquez-Prado J., Gao Y., Zheng Y., Gutkind J.S. Direct interaction of p21-activated kinase 4 with PDZ-RhoGEF, a G protein-linked Rho guanine exchange factor. Journal of Biological Chemistry 2004, 279:6182-6189.
107. Chikumi H., Barac A., Behbahani B., Gao Y., Teramoto H., Zheng Y., et al. Homo- and hetero-oligomerization of PDZ-RhoGEF, LARG and p115RhoGEF by their C-terminal region regulates their in vivo Rho GEF activity and transforming potential. Oncogene 2004, 23:233-240.